Clinical Trials Logo

Filter by:
NCT ID: NCT00914628 Terminated - Clinical trials for Acute Leukemia (Category)

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

TK008
Start date: April 12, 2010
Phase: Phase 3
Study type: Interventional

The main objective of this randomized trial is to compare disease-free survival (DFS) in high risk leukemia patients who underwent haploidentical HCT followed by an add back strategy of HSV-Tk donor lymphocytes or standard haploidentical HCT

NCT ID: NCT00912288 Terminated - Alzheimer Disease Clinical Trials

A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Start date: September 2009
Phase: Phase 3
Study type: Interventional

No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.

NCT ID: NCT00911443 Completed - Malignant Melanoma Clinical Trials

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

Start date: July 2002
Phase: Phase 2
Study type: Interventional

The purpose of the study is to test safety and efficacy of different doses of thymosin alpha 1 (1.6 mg, 3.2 mg, and 6.4 mg) in combination with dacarbazine and with or without Interferon alpha in treating patients affected by stage IV melanoma. Primary end-point is Tumor Response evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST). Secondary end-points are Overall Survival and Progression Free Survival. Ninety-five patients are allocated to each arm to test the hypothesis that P0 <= 0.05 vs the alternative hypothesis that P1 >= 0.15 (alpha = 5%, within-group statistical analysis beta = 95%).

NCT ID: NCT00910910 Completed - Clinical trials for B-Cell Chronic Lymphocytic Leukemia

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

ORIGIN
Start date: October 13, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil.

NCT ID: NCT00910429 Completed - Clinical trials for Pulmonary Hypertension

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

CHEST-2
Start date: July 1, 2009
Phase: Phase 3
Study type: Interventional

Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.

NCT ID: NCT00903838 Terminated - Clinical trials for Advanced Stage Parkinson's Disease

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Start date: September 2009
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double blind, pramipexole-controlled parallel group study of pardoprunox as adjunctive treatment to levodopa.

NCT ID: NCT00902785 Terminated - Clinical trials for Age-related Macular Degeneration (AMD)

A Study Of Early Markers Of Choroidal Neovascularization

Start date: March 2008
Phase: Phase 4
Study type: Observational

Identify early markers of choroidal neovascularization (CNV) in the fellow eye of a patient with CNV in the other eye due to age-related macular degeneration with the expectation of being able to identify patients in need of intervention.

NCT ID: NCT00898560 Completed - Partial Epilepsy Clinical Trials

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate whether multiple-dose administration of eslicarbazepine acetate (ESL, BIA 2-093) 800 mg once-daily (QD) affects the pharmacokinetics and tolerability of the components of a combined oral contraceptive (ethinyloestradiol and levonorgestrel).

NCT ID: NCT00893867 Terminated - Clinical trials for Acute Ischemic Stroke

Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke

MACSI
Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to determine if intravenous administration of the metal ion trapping agent DP-b99 up to 9 hours following acute ischemic stroke onset, and then for 3 additional days (4 consecutive days in total) is effective in improving long term outcome. Patients will be followed up for 3 months after the stroke.

NCT ID: NCT00893243 Completed - Dry Eye Syndrome Clinical Trials

Efficacy Comparative Study Between Tears Again®, Opticol® and Optive®

Start date: n/a
Phase: N/A
Study type: Observational

Primary Purpose: - To compare the efficacy in treating dry eye syndrome in contact lens wearers or computer users of Tears Again® versus Opticol® versus Optive® Secondary Purpose: - Subjective evaluation of symptomatology - Evaluation of preference in different kind of administration - spray versus monodoses versus multi-doses